🔗 Visit the ClinicalTrials.gov page for NCT00078585
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. | J Clin Oncol | 2010 | 9.86 |
| 2 | Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. | Int J Mol Sci | 2013 | 0.88 |
| 3 | ABO blood type correlates with survival on prostate cancer vaccine therapy. | Oncotarget | 2015 | 0.79 |
| 4 | DNA vaccination for prostate cancer: key concepts and considerations. | Cancer Nanotechnol | 2015 | 0.78 |
| 5 | Androgen pathway resistance in prostate cancer and therapeutic implications. | Expert Opin Pharmacother | 2015 | 0.77 |
| 6 | New clinical advances in immunotherapy for the treatment of solid tumours. | Immunology | 2015 | 0.76 |